GenEditBio
geneditbio.com
Actively hiring
Cell & Gene Therapy
Health Care
Biotechnology
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Backers
1
Qiming Venture Partners
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Backed byfrom the funds' portfolios and accelerator catalogs
Qiming Venture Partners Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Transforming Treatment About Vironexis was founded in 2021 to translate a groundbreaking discovery — pioneered by our co-founder Timothy…
Lift to Zenith with Novel Myeloid Engager Therapeutics. To maximize the drugability potential, we target approaches to improve clinical…
首页 关于我们 技术平台 产品管线 临床试验 投资者关系和媒体 新闻资讯 投资者关系 职业生涯 人才培养 院士(专家)/博士后工作站 人才招聘 联系我们 EN — CN 联系我们 CN — EN 关于我们 技术平台 产品管线 临床试验 投资者关系和媒体 新闻资讯 投资者关系…
ABOUT US Company Overview Leadership Company History SAB, Partners & Investors Contact Us TECHNOLOGY & INNOVATION Stem Cell Therapy Drug…
Enabling genetic medicines: We enable the safe, efficient delivery of gene therapies using LNP formulations customized by target, cargo and…
Characterize AAV, LNP, EVs and viral vectors from 20 to 300 nm. Measure empty/full capsid ratio, concentration and aggregation — label-free.
News
GenEditBio Receives FDA Clearance of IND Application for Its Lead In Vivo Genome-Editing Program GEB-101 for TGFBI Corneal Dystrophy
/PRNewswire/ -- GenEditBio Limited ("GenEditBio"), a clinical-stage biotechnology startup focusing on genome-editing therapeutic solutions, today announced...
Read more
Report
GenEditBio Limited: GenEditBio Receives FDA Clearance of IND Application for Its Lead In Vivo Genome-Editing Program GEB-101 for TGFBI Corneal Dystrophy
HONG KONG, Jan. 5, 2026 /PRNewswire/ -- GenEditBio Limited ("GenEditBio"), a clinical-stage biotechnology startup focusing on genome-editing therapeutic solutions, today announced that the U.S.
Read more
Report
ToolGen and GenEditBio Enter Strategic Cross-License Agreement to Accelerate Development of Innovative Genome-Editing Therapeutics
ToolGen Inc. (KOSDAQ: 199800), a leading genome editing company based in Korea, announced today that it has entered into a strategic cross-license agreement with GenEditBio Limited ("GenEditBio"), a Hong Kong-headquartered clinical-stage biotechnology com
Read more
Report
ToolGen and GenEditBio Enter Strategic Cross-License Agreement to Accelerate Development of Innovative Genome-Editing Therapeutics
Integrates ToolGen's best-in-class CRISPR-Cas9 platform with GenEditBio's industry-leading lipid nanoparticle (LNP) delivery technology Pursues a "once-and-done"
Read more
Report
GenEditBio and ToolGen Enter Strategic Cross-License Agreement to Accelerate Development of Innovative Genome-Editing Therapeutics
GenEditBio Limited ("GenEditBio"), a Hong Kong-headquartered clinical-stage biotechnology company specializing in novel deliveries, including lipid nanoparticle (LNP)-based delivery systems, announced today that it has entered into a strategic cross-licen
Read more
Report
GenEditBio and ToolGen Enter Strategic Cross-License Agreement to Accelerate Development of Innovative Genome-Editing Therapeutics
/PRNewswire/ -- GenEditBio Limited ("GenEditBio"), a Hong Kong-headquartered clinical-stage biotechnology company specializing in novel deliveries, including...
Read more
Report
First subject dosed in trial of GenEditBio's GEB-101 for corneal dystrophy
The trial is conducted in partnership with the Eye & ENT Hospital of Fudan University in China.
Read more
Report
Offices
Where the company hires and what each office is for
Cities
2
Hiring now
0
Countries
2
Loading the map
Headquarters
Builds here
Office with open vacancies
No open vacancies right now Tap a pin for the office
Beijing
China
HQ
Hong Kong
Hong Kong
Regional office
Careers
HONG KONG Unit 101-102, Building 6W, 6 Science Park West Avenue, Hong Kong